Cargando…

Efficacy and safety of radiofrequency ablation for calcified benign thyroid nodules: results of over 5 years' follow-up

PURPOSE: To evaluate the efficacy and safety of radiofrequency ablation (RFA) for treating calcified benign thyroid nodules (CBTNs). METHODS: Fifty-two patients with 52 CBTNs who underwent RFA in our hospital were included in this retrospective study. According to the size of calcifications, CBTNs w...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yi, He, Hongying, Li, Wen, Zhao, Jiahang, Ge, Naiqiao, Zhang, Yan, Luo, Yukun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027040/
https://www.ncbi.nlm.nih.gov/pubmed/35459125
http://dx.doi.org/10.1186/s12880-022-00795-5
_version_ 1784691261827973120
author Li, Yi
He, Hongying
Li, Wen
Zhao, Jiahang
Ge, Naiqiao
Zhang, Yan
Luo, Yukun
author_facet Li, Yi
He, Hongying
Li, Wen
Zhao, Jiahang
Ge, Naiqiao
Zhang, Yan
Luo, Yukun
author_sort Li, Yi
collection PubMed
description PURPOSE: To evaluate the efficacy and safety of radiofrequency ablation (RFA) for treating calcified benign thyroid nodules (CBTNs). METHODS: Fifty-two patients with 52 CBTNs who underwent RFA in our hospital were included in this retrospective study. According to the size of calcifications, CBTNs were divided into two groups: the punctate echogenic foci (PEF) group and macrocalcification group. Moreover, the macrocalcification group was further subdivided into two groups, the strong group and the weak group, based on their morphologic characteristics. After the RFA procedure, routine ultrasound (US) and clinical evaluation were performed at 1, 3, 6 and 12 months postoperatively and every 12 months thereafter. RESULTS: The mean follow-up time was 68.98 ± 7.68 months (60–87 months), and the 5-year mean volume reduction rate (VRR) after RFA was 92.95%, with a complication rate of 0.6% (3/52). The mean initial volume of the macrocalcification group was significantly larger than that of the PEF group (9.94 ± 24.60 ml vs. 0.23 ± 0.22 ml, respectively; P = 0.011). Thus, their VRRs were not comparable between the two groups. However, baseline characteristics did not show statistically significant differences between the strong and weak macrocalcification subgroups. The VRRs of the strong subgroup were significantly lower than those of the weak subgroup at the 3-year, 4-year, and 5-year follow-ups. CONCLUSION: RFA was effective and safe for treating CBTNs. Strong macrocalcification was related to the VRR of CBTNs after the RFA procedure.
format Online
Article
Text
id pubmed-9027040
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-90270402022-04-23 Efficacy and safety of radiofrequency ablation for calcified benign thyroid nodules: results of over 5 years' follow-up Li, Yi He, Hongying Li, Wen Zhao, Jiahang Ge, Naiqiao Zhang, Yan Luo, Yukun BMC Med Imaging Research PURPOSE: To evaluate the efficacy and safety of radiofrequency ablation (RFA) for treating calcified benign thyroid nodules (CBTNs). METHODS: Fifty-two patients with 52 CBTNs who underwent RFA in our hospital were included in this retrospective study. According to the size of calcifications, CBTNs were divided into two groups: the punctate echogenic foci (PEF) group and macrocalcification group. Moreover, the macrocalcification group was further subdivided into two groups, the strong group and the weak group, based on their morphologic characteristics. After the RFA procedure, routine ultrasound (US) and clinical evaluation were performed at 1, 3, 6 and 12 months postoperatively and every 12 months thereafter. RESULTS: The mean follow-up time was 68.98 ± 7.68 months (60–87 months), and the 5-year mean volume reduction rate (VRR) after RFA was 92.95%, with a complication rate of 0.6% (3/52). The mean initial volume of the macrocalcification group was significantly larger than that of the PEF group (9.94 ± 24.60 ml vs. 0.23 ± 0.22 ml, respectively; P = 0.011). Thus, their VRRs were not comparable between the two groups. However, baseline characteristics did not show statistically significant differences between the strong and weak macrocalcification subgroups. The VRRs of the strong subgroup were significantly lower than those of the weak subgroup at the 3-year, 4-year, and 5-year follow-ups. CONCLUSION: RFA was effective and safe for treating CBTNs. Strong macrocalcification was related to the VRR of CBTNs after the RFA procedure. BioMed Central 2022-04-22 /pmc/articles/PMC9027040/ /pubmed/35459125 http://dx.doi.org/10.1186/s12880-022-00795-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Li, Yi
He, Hongying
Li, Wen
Zhao, Jiahang
Ge, Naiqiao
Zhang, Yan
Luo, Yukun
Efficacy and safety of radiofrequency ablation for calcified benign thyroid nodules: results of over 5 years' follow-up
title Efficacy and safety of radiofrequency ablation for calcified benign thyroid nodules: results of over 5 years' follow-up
title_full Efficacy and safety of radiofrequency ablation for calcified benign thyroid nodules: results of over 5 years' follow-up
title_fullStr Efficacy and safety of radiofrequency ablation for calcified benign thyroid nodules: results of over 5 years' follow-up
title_full_unstemmed Efficacy and safety of radiofrequency ablation for calcified benign thyroid nodules: results of over 5 years' follow-up
title_short Efficacy and safety of radiofrequency ablation for calcified benign thyroid nodules: results of over 5 years' follow-up
title_sort efficacy and safety of radiofrequency ablation for calcified benign thyroid nodules: results of over 5 years' follow-up
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027040/
https://www.ncbi.nlm.nih.gov/pubmed/35459125
http://dx.doi.org/10.1186/s12880-022-00795-5
work_keys_str_mv AT liyi efficacyandsafetyofradiofrequencyablationforcalcifiedbenignthyroidnodulesresultsofover5yearsfollowup
AT hehongying efficacyandsafetyofradiofrequencyablationforcalcifiedbenignthyroidnodulesresultsofover5yearsfollowup
AT liwen efficacyandsafetyofradiofrequencyablationforcalcifiedbenignthyroidnodulesresultsofover5yearsfollowup
AT zhaojiahang efficacyandsafetyofradiofrequencyablationforcalcifiedbenignthyroidnodulesresultsofover5yearsfollowup
AT genaiqiao efficacyandsafetyofradiofrequencyablationforcalcifiedbenignthyroidnodulesresultsofover5yearsfollowup
AT zhangyan efficacyandsafetyofradiofrequencyablationforcalcifiedbenignthyroidnodulesresultsofover5yearsfollowup
AT luoyukun efficacyandsafetyofradiofrequencyablationforcalcifiedbenignthyroidnodulesresultsofover5yearsfollowup